Covered recipient · General Payments record
SAMER N NAKHLE
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$108,073.90
234 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $96,567.50 | 59 |
| Travel and Lodging | $7,978.00 | 59 |
| Food and Beverage | $3,528.40 | 116 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $84,352.32 | 151 |
| Novo Nordisk Inc | $21,098.03 | 38 |
| Ascendis Pharma, Inc. | $1,774.61 | 2 |
| Abbott Laboratories | $175.80 | 9 |
| AstraZeneca Pharmaceuticals LP | $129.80 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $66.97 | 3 |
| Dexcom, Inc. | $56.28 | 3 |
| Mannkind Corporation | $45.09 | 3 |
| Xeris Pharmaceuticals, Inc. | $44.87 | 3 |
| LIFESCAN, INC. | $43.29 | 2 |
| Amryt Pharma Holdings Ltd | $37.59 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.36 | 2 |
| Amgen Inc. | $32.98 | 2 |
| Radius Health, Inc. | $21.27 | 1 |
| Amarin Pharma Inc. | $19.63 | 1 |
| Zealand Pharma US, Inc. | $19.33 | 1 |
| Endo Pharmaceuticals Inc. | $16.77 | 1 |
| Ascensia Diabetes Care Us Inc. | $16.48 | 1 |
| ABBVIE INC. | $16.00 | 1 |
| Horizon Therapeutics plc | $15.55 | 1 |
| SANOFI-AVENTIS U.S. LLC | $15.05 | 1 |
| Esperion Therapeutics, Inc. | $14.29 | 1 |
| Corcept Therapeutics | $13.84 | 1 |
| Amneal Pharmaceuticals LLC | $12.70 | 1 |
Page 5 of 5; records 201–234 of 234 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SAMER N NAKHLE
NPI 1841281771 · CMS profile ID 356388
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
LAS VEGAS, NV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–234 of 234 matching records. This page contains 34 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841281771?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–234 of 234 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841281771?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–234 of 234 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841281771?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–234 of 234 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1841281771?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
234 matching records · $108,073.90 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–234 of 234.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $24.57 | 03/25/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918294639 | CMS |
| Amneal Pharmaceuticals LLC | $12.70 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956590285 | CMS |
| Lilly USA, LLC | $28.08 | 03/24/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918294637 | CMS |
| Lilly USA, LLC | $9.36 | 03/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918321617 | CMS |
| Lilly USA, LLC | $31.59 | 03/22/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280767 | CMS |
| Lilly USA, LLC | $0.39 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918363407 | CMS |
| Lilly USA, LLC | $20.07 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918363443 | CMS |
| Lilly USA, LLC | $672.96 | 03/18/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280731 | CMS |
| Abbott Laboratories | $18.35 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920559095 | CMS |
| Lilly USA, LLC | $1,800.00 | 03/16/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280765 | CMS |
| Lilly USA, LLC | $675.00 | 03/16/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918296681 | CMS |
| Amarin Pharma Inc. | $19.63 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 913945755 | CMS |
| Lilly USA, LLC | $9.09 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918363441 | CMS |
| Ascendis Pharma, Inc. | $570.72 | 03/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942553239 | CMS |
| Lilly USA, LLC | $675.00 | 03/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918296679 | CMS |
| Lilly USA, LLC | $1,800.00 | 03/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918321615 | CMS |
| Lilly USA, LLC | $8.74 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280769 | CMS |
| Novo Nordisk Inc | $16.32 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898547047 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.40 | 03/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915863685 | CMS |
| Xeris Pharmaceuticals, Inc. | $13.82 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946491643 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $27.00 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930131737 | CMS |
| LIFESCAN, INC. | $24.19 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 919452787 | CMS |
| Amgen Inc. | $13.36 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939816403 | CMS |
| Lilly USA, LLC | $675.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280763 | CMS |
| Lilly USA, LLC | $1,800.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918321611 | CMS |
| Abbott Laboratories | $29.84 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914278447 | CMS |
| Lilly USA, LLC | $675.00 | 02/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280761 | CMS |
| Lilly USA, LLC | $1,800.00 | 02/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918363439 | CMS |
| Lilly USA, LLC | $8.61 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918321613 | CMS |
| Lilly USA, LLC | $9.31 | 02/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918298531 | CMS |
| Novo Nordisk Inc | $19.77 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899333231 | CMS |
| Novo Nordisk Inc | $23.46 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899333247 | CMS |
| Mannkind Corporation | $13.78 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942762287 | CMS |
| Esperion Therapeutics, Inc. | $14.29 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947273167 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,176,620.85 | 99 |
| PY2024 | Recipient | $73,765.20 | 6 |
| PY2024 | Principal investigator | $2,678,158.95 | 361 |
| PY2023 | Recipient | $2,905.02 | 4 |
| PY2023 | Principal investigator | $2,422,525.26 | 482 |
| PY2022 | Recipient | $108,874.00 | 3 |
| PY2022 | Principal investigator | $1,179,953.77 | 761 |
| PY2021 | Principal investigator | $1,638,336.04 | 1,369 |
| PY2020 | Recipient | $1,962.53 | 4 |
| PY2020 | Principal investigator | $1,001,795.07 | 638 |
| PY2019 | Recipient | $6,159.46 | 26 |
| PY2019 | Principal investigator | $1,910,652.40 | 419 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
99 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202532554 |
| Principal investigator 1 | Dexcom, Inc. | $570.00 | 12/23/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961954 |
| Principal investigator 1 | Dexcom, Inc. | $2,485.00 | 12/23/2025 | Non-covered Recipient Entity Palm Research Center | EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR | No dispute reported | 06/30/2026 | 1250961960 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 12/17/2025 | Non-covered Recipient Entity Palm Research Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220714282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 12/17/2025 | Non-covered Recipient Entity Palm Research Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220714284 |
| Principal investigator 1 | ABBVIE INC. | $1,430.00 | 12/16/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202530622 |
| Principal investigator 1 | ABBVIE INC. | $3,300.00 | 12/11/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202530166 |
| Principal investigator 1 | ABBVIE INC. | $2,700.00 | 12/10/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529878 |
| Principal investigator 1 | ABBVIE INC. | $11,543.70 | 12/05/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529392 |
| Principal investigator 1 | Dexcom, Inc. | $960.00 | 12/02/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961958 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 11/20/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN8640-4515 | No dispute reported | 06/30/2026 | 1214103071 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 11/20/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN8640-4515 | No dispute reported | 06/30/2026 | 1214104227 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $14,828.00 | 11/11/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246790313 |
| Principal investigator 1 | ABBVIE INC. | $167,385.72 | 11/05/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202523095 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,964.95 | 10/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS15 | No dispute reported | 06/30/2026 | 1246789764 |
| Principal investigator 1 | Novo Nordisk AS | $6,400.00 | 10/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213706685 |
| Principal investigator 1 | Novo Nordisk AS | $130.00 | 10/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213760705 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $26,650.00 | 10/20/2025 | Non-covered Recipient Entity PALM MEDICAL GROUP, LLC | a phase two randomized doubleblinded placebocontrolled dose rangefinding multicenter study to evaluate the efficacy safety and pharmacokinetics of alxn2420 a growth hormone receptor antagonist administered subcutaneously in combination with somatostatin analogs in adult participants with acromegaly | No dispute reported | 06/30/2026 | 1185542552 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $360.00 | 10/09/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223286671 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,000.00 | 10/08/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246788410 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,720.00 | 10/08/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246788413 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,250.00 | 10/08/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246788417 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,500.00 | 10/08/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246788421 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,930.80 | 10/08/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246788424 |
| Principal investigator 1 | Dexcom, Inc. | $2,392.00 | 10/07/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961952 |
| Principal investigator 1 | Dexcom, Inc. | $14,796.00 | 10/07/2025 | Non-covered Recipient Entity Palm Research Center | EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR | No dispute reported | 06/30/2026 | 1250961956 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,700.00 | 10/03/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246787935 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,400.00 | 10/03/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246787939 |
| Principal investigator 1 | Novo Nordisk AS | $750.00 | 09/17/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213767881 |
| Principal investigator 1 | Novo Nordisk AS | $2,250.00 | 09/17/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213786513 |
| Principal investigator 1 | Novo Nordisk AS | $1,250.00 | 09/17/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213846765 |
| Principal investigator 1 | Dexcom, Inc. | $4,000.00 | 09/16/2025 | Non-covered Recipient Entity Palm Research Center | Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects | No dispute reported | 06/30/2026 | 1250961964 |
| Principal investigator 1 | Dexcom, Inc. | $4,605.00 | 09/09/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961944 |
| Principal investigator 1 | Dexcom, Inc. | $590.00 | 09/03/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961946 |
| Principal investigator 1 | Dexcom, Inc. | $21,309.00 | 08/19/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961942 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $360.00 | 08/14/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223284235 |
| Principal investigator 1 | Globus Medical, Inc. | $1,000.00 | 08/07/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy | No dispute reported | 06/30/2026 | 1236865543 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,298.75 | 08/06/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS9 | No dispute reported | 06/30/2026 | 1246786065 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,956.40 | 08/06/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | IS354CS15 | No dispute reported | 06/30/2026 | 1246786258 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $7,125.00 | 07/30/2025 | Non-covered Recipient Entity Palm Research Center Inc | foresiGHt extension | No dispute reported | 06/30/2026 | 1233996553 |
| Principal investigator 1 | Dexcom, Inc. | $9,015.00 | 07/22/2025 | Non-covered Recipient Entity Palm Research Center | EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR | No dispute reported | 06/30/2026 | 1250961948 |
| Principal investigator 1 | Dexcom, Inc. | $1,425.00 | 07/22/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961950 |
| Principal investigator 1 | Novo Nordisk AS | $909.35 | 07/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213810273 |
| Principal investigator 1 | ABBVIE INC. | $27,789.75 | 07/02/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202496121 |
| Principal investigator 1 | Eli Lilly and Company | $195,620.00 | 06/16/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187887766 |
| Principal investigator 1 | Dexcom, Inc. | $6,014.00 | 06/10/2025 | Non-covered Recipient Entity Palm Research Center | EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR | No dispute reported | 06/30/2026 | 1250961936 |
| Principal investigator 1 | Eli Lilly and Company | $506,441.00 | 06/10/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) | No dispute reported | 06/30/2026 | 1187890264 |
| Principal investigator 1 | ABBVIE INC. | $64,681.98 | 06/03/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488565 |
| Principal investigator 1 | ABBVIE INC. | $850.00 | 06/03/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488567 |
| Principal investigator 1 | Dexcom, Inc. | $7,136.00 | 06/03/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961938 |
| Principal investigator 1 | Globus Medical, Inc. | $29,128.00 | 05/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy | No dispute reported | 06/30/2026 | 1236866047 |
| Principal investigator 1 | Novo Nordisk AS | $2,307.00 | 05/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | NN9535-4801 | No dispute reported | 06/30/2026 | 1213822370 |
| Principal investigator 1 | Dexcom, Inc. | $13,000.00 | 05/13/2025 | Non-covered Recipient Entity Palm Research Center | EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR | No dispute reported | 06/30/2026 | 1250961934 |
| Principal investigator 1 | ABBVIE INC. | $27,885.66 | 05/07/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483351 |
| Principal investigator 1 | Globus Medical, Inc. | $3,810.00 | 05/07/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy | No dispute reported | 06/30/2026 | 1236865881 |
| Principal investigator 1 | Eli Lilly and Company | $10,501.79 | 05/01/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187890268 |
| Principal investigator 1 | ABBVIE INC. | $7,100.00 | 04/28/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202479778 |
| Principal investigator 1 | Dexcom, Inc. | $5,475.00 | 04/22/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961940 |
| Principal investigator 1 | Globus Medical, Inc. | $11,364.00 | 04/10/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy | No dispute reported | 06/30/2026 | 1236866045 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $360.00 | 04/10/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223277810 |
| Principal investigator 1 | ABBVIE INC. | $17,911.02 | 04/03/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202473109 |
| Principal investigator 1 | Novo Nordisk AS | $25,794.13 | 03/31/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | EX9924-4473 | No dispute reported | 06/30/2026 | 1213724781 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,080.00 | 03/14/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223276359 |
| Principal investigator 1 | Dexcom, Inc. | $4,090.00 | 03/11/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961930 |
| Principal investigator 1 | ABBVIE INC. | $44,495.34 | 03/07/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202461881 |
| Principal investigator 1 | Dexcom, Inc. | $670.00 | 03/04/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961926 |
| Principal investigator 1 | Eli Lilly and Company | $737.50 | 03/04/2025 | Non-covered Recipient Entity TRIBE CLINICAL RESEARCH LLC | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187893620 |
| Principal investigator 1 | Amgen Inc. | $80,361.55 | 02/25/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246646269 |
| Principal investigator 1 | Amgen Inc. | $189,950.07 | 02/25/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246646278 |
| Principal investigator 1 | Dexcom, Inc. | $2,501.00 | 02/25/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961928 |
| Principal investigator 1 | Novo Nordisk AS | $6,480.00 | 02/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | EX9924-4473 | No dispute reported | 06/30/2026 | 1213788012 |
| Principal investigator 1 | Novo Nordisk AS | $4,900.00 | 02/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | EX9924-4473 | No dispute reported | 06/30/2026 | 1213837418 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $360.00 | 02/13/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223275233 |
| Principal investigator 1 | ABBVIE INC. | $36,278.82 | 02/06/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449639 |
| Principal investigator 1 | Eli Lilly and Company | $1,103.26 | 01/31/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187885252 |
| Principal investigator 1 | Eli Lilly and Company | $1,887.86 | 01/31/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187887764 |
| Principal investigator 1 | Eli Lilly and Company | $1,220.10 | 01/31/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187888314 |
| Principal investigator 1 | Globus Medical, Inc. | $3,210.00 | 01/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER | A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy | No dispute reported | 06/30/2026 | 1236865713 |
| Principal investigator 1 | Shionogi Inc | $3,815.70 | 01/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250719913 |
| Principal investigator 1 | Shionogi Inc | $3,916.11 | 01/29/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults | No dispute reported | 06/30/2026 | 1250719918 |
| Principal investigator 1 | Eli Lilly and Company | $26,650.00 | 01/28/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187887758 |
| Principal investigator 1 | Eli Lilly and Company | $713.70 | 01/27/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187887762 |
| Principal investigator 1 | Eli Lilly and Company | $1,091.82 | 01/27/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187888312 |
| Principal investigator 1 | Eli Lilly and Company | $6,107.38 | 01/27/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187889916 |
| Principal investigator 1 | Eli Lilly and Company | $3,341.91 | 01/22/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187885258 |
| Principal investigator 1 | Amgen Inc. | $55,336.54 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246646264 |
| Principal investigator 1 | Eli Lilly and Company | $318,608.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1187885250 |
| Principal investigator 1 | Eli Lilly and Company | $364,983.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187887488 |
| Principal investigator 1 | Eli Lilly and Company | $20,298.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187888308 |
| Principal investigator 1 | Eli Lilly and Company | $31,482.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187889356 |
| Principal investigator 1 | Eli Lilly and Company | $51,431.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187889750 |
| Principal investigator 1 | Eli Lilly and Company | $78,484.00 | 01/21/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187889752 |
| Principal investigator 1 | Eli Lilly and Company | $97,969.00 | 01/17/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1187889754 |
| Principal investigator 1 | Eli Lilly and Company | $169,965.00 | 01/17/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187889756 |
| Principal investigator 1 | Eli Lilly and Company | $1,116.75 | 01/16/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187887486 |
| Principal investigator 1 | Dexcom, Inc. | $3,623.00 | 01/07/2025 | Non-covered Recipient Entity Palm Research Center | CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY | No dispute reported | 06/30/2026 | 1250961932 |
| Principal investigator 1 | Dexcom, Inc. | $121.82 | 01/07/2025 | Non-covered Recipient Entity Palm Research Center | Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects | No dispute reported | 06/30/2026 | 1250961962 |
| Principal investigator 1 | Eli Lilly and Company | $210,945.00 | 01/07/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187887490 |
| Principal investigator 1 | Amgen Inc. | $36,924.38 | 01/02/2025 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246646260 |